Close Menu

NEW YORK – Biomedical software startup BostonGene on Tuesday announced a research collaboration with Thomas Jefferson University and its Sidney Kimmel Cancer Center-Jefferson Health affiliate to study the molecular, cellular, and immunologic profiles of patients with squamous cell carcinoma of the head and neck who are treated with two existing drugs.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.